603 related articles for article (PubMed ID: 26420955)
1. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.
Mori S; Fujiyama S
World J Gastroenterol; 2015 Sep; 21(36):10274-89. PubMed ID: 26420955
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Lee YH; Bae SC; Song GG
Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
[TBL] [Abstract][Full Text] [Related]
5. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G
Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
[TBL] [Abstract][Full Text] [Related]
7. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.
Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N
Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752
[TBL] [Abstract][Full Text] [Related]
8. Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.
Ahn SS; Jung SM; Song JJ; Park YB; Park JY; Lee SW
Yonsei Med J; 2018 May; 59(3):452-456. PubMed ID: 29611409
[TBL] [Abstract][Full Text] [Related]
9. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
Ito S
Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
[TBL] [Abstract][Full Text] [Related]
10. Reduction or cessation of antiviral agents in hepatitis B virus carriers treated with biologic agents.
Ghang B; Lee D; Hwang I; Lee CK; Yoo B; Kim YG
Clin Exp Rheumatol; 2018; 36(1):170. PubMed ID: 29352838
[No Abstract] [Full Text] [Related]
11. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
12. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
13. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.
Stine JG; Khokhar OS; Charalambopoulos J; Shanmugam VK; Lewis JH
Arthritis Care Res (Hoboken); 2010 May; 62(5):704-11. PubMed ID: 20461789
[TBL] [Abstract][Full Text] [Related]
14. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis.
Moghoofei M; Mostafaei S; Ashraf-Ganjouei A; Kavosi H; Mahmoudi M
Microb Pathog; 2018 Jan; 114():436-443. PubMed ID: 29223453
[TBL] [Abstract][Full Text] [Related]
15. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351
[TBL] [Abstract][Full Text] [Related]
16. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N
J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
[TBL] [Abstract][Full Text] [Related]
18. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
Su J; Long L; Zou K
Clin Rheumatol; 2018 Dec; 37(12):3201-3214. PubMed ID: 29637482
[TBL] [Abstract][Full Text] [Related]
19. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
[TBL] [Abstract][Full Text] [Related]
20. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Wu Y; Huang H; Luo Y
Front Immunol; 2020; 11():610500. PubMed ID: 33613534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]